GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab AS (NAS:GMAB) » Definitions » E10

GMAB (Genmab AS) E10 : $0.71 (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Genmab AS E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Genmab AS's adjusted earnings per share data for the three months ended in Sep. 2024 was $0.295. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $0.71 for the trailing ten years ended in Sep. 2024.

During the past 12 months, Genmab AS's average E10 Growth Rate was 17.70% per year. During the past 3 years, the average E10 Growth Rate was 34.70% per year. During the past 5 years, the average E10 Growth Rate was 70.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Genmab AS was 113.00% per year. The lowest was 34.70% per year. And the median was 59.30% per year.

As of today (2024-12-13), Genmab AS's current stock price is $20.17. Genmab AS's E10 for the quarter that ended in Sep. 2024 was $0.71. Genmab AS's Shiller PE Ratio of today is 28.41.

During the past 13 years, the highest Shiller PE Ratio of Genmab AS was 477.78. The lowest was 30.52. And the median was 110.88.


Genmab AS E10 Historical Data

The historical data trend for Genmab AS's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab AS E10 Chart

Genmab AS Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.28 0.35 0.50 0.61

Genmab AS Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.61 0.62 0.66 0.71

Competitive Comparison of Genmab AS's E10

For the Biotechnology subindustry, Genmab AS's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Shiller PE Ratio falls into.



Genmab AS E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab AS's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=0.295/118.9000*118.9000
=0.295

Current CPI (Sep. 2024) = 118.9000.

Genmab AS Quarterly Data

per share eps CPI Adj_EPS
201412 0.020 99.400 0.024
201503 0.053 100.200 0.063
201506 0.004 100.300 0.005
201509 0.035 100.200 0.042
201512 0.094 99.800 0.112
201603 -0.003 100.200 -0.004
201606 0.041 100.600 0.048
201609 0.046 100.200 0.055
201612 0.193 100.300 0.229
201703 0.004 101.200 0.005
201706 0.075 101.200 0.088
201709 -0.001 101.800 -0.001
201712 0.201 101.300 0.236
201803 0.053 101.700 0.062
201806 0.066 102.300 0.077
201809 0.045 102.400 0.052
201812 0.205 102.100 0.239
201903 0.018 102.900 0.021
201906 0.020 102.900 0.023
201909 0.122 102.900 0.141
201912 0.342 102.900 0.395
202003 0.060 103.300 0.069
202006 0.775 103.200 0.893
202009 0.127 103.500 0.146
202012 0.143 103.400 0.164
202103 0.266 104.300 0.303
202106 0.075 105.000 0.085
202109 0.213 105.800 0.239
202112 0.153 106.600 0.171
202203 0.104 109.900 0.113
202206 0.407 113.600 0.426
202209 0.521 116.400 0.532
202212 0.110 115.900 0.113
202303 0.046 117.300 0.047
202306 0.295 116.400 0.301
202309 0.457 117.400 0.463
202312 0.155 116.700 0.158
202403 0.294 118.400 0.295
202406 0.313 118.500 0.314
202409 0.295 118.900 0.295

Add all the adjusted EPS together and divide 10 will get our e10.


Genmab AS  (NAS:GMAB) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Genmab AS's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=20.17/0.71
=28.41

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Genmab AS was 477.78. The lowest was 30.52. And the median was 110.88.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Genmab AS E10 Related Terms

Thank you for viewing the detailed overview of Genmab AS's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab AS Business Description

Address
Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.